Barclays Initiates Coverage on Amgen (NASDAQ:AMGN)

Equities research analysts at Barclays initiated coverage on shares of Amgen (NASDAQ:AMGN) in a research report issued to clients and investors on Friday,Benzinga reports. The firm set an “equal weight” rating and a $350.00 price target on the medical research company’s stock. Barclays‘s price target would suggest a potential downside of 6.60% from the company’s previous close.

Other research analysts have also issued reports about the stock. Morgan Stanley upped their target price on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. HSBC reiterated a “buy” rating and set a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Truist Financial boosted their target price on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Piper Sandler increased their price target on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, BMO Capital Markets boosted their price objective on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $351.76.

Amgen Stock Down 0.2%

Shares of NASDAQ AMGN opened at $374.75 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The business has a 50-day moving average of $343.21 and a 200-day moving average of $316.32. The firm has a market capitalization of $202.02 billion, a price-to-earnings ratio of 26.34, a PEG ratio of 3.80 and a beta of 0.46. Amgen has a 12 month low of $261.43 and a 12 month high of $385.12.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period in the previous year, the business posted $5.31 earnings per share. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts expect that Amgen will post 20.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amgen

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. State Street Corp increased its stake in shares of Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after buying an additional 1,287,310 shares during the period. Capital World Investors increased its stake in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after buying an additional 4,302,237 shares during the period. Capital International Investors raised its holdings in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after acquiring an additional 282,219 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Rothschild & Co Redburn says Amgen’s stock price is expected to rise — a bullish analyst view that could support upside if reiterated or joined by others. Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says
• Neutral Sentiment: Amgen priced $4.0 billion of senior unsecured notes across multiple maturities — this increases debt but provides liquidity; impact depends on use of proceeds (buybacks, M&A, refinancing). Investors should watch tenor and coupon details to assess financing cost and leverage effects. Amgen Prices $4 Billion Senior Unsecured Notes Offering
• Neutral Sentiment: Amgen has been a “trending” ticker on sites like Zacks and Yahoo — heightened attention can lift liquidity and volatility but is not a directional fundamental catalyst by itself. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: “Here’s What the Street is Saying” roundups summarize mixed analyst commentary — useful for context but check individual firm views for conviction and PTs. Here’s What the Street is Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Short-interest data reported for mid-February appears to show 0 shares (NaN/incomplete) and a 0.0 days-to-cover metric — likely a reporting glitch; no reliable evidence here of a significant short squeeze or increase in bearish positioning.
• Negative Sentiment: Barclays initiated coverage with an “equal-weight” rating and a $350 price target, implying roughly a mid-single-digit downside from recent levels — this new coverage (and PT below the current price) is a near-term headwind for sentiment. Barclays initiates coverage of Amgen (AMGN) with equal-weight recommendation

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.